U.S. markets open in 3 hours 26 minutes
  • S&P Futures

    4,450.00
    +4.25 (+0.10%)
     
  • Dow Futures

    34,784.00
    +110.00 (+0.32%)
     
  • Nasdaq Futures

    15,277.75
    -41.00 (-0.27%)
     
  • Russell 2000 Futures

    2,252.70
    +8.70 (+0.39%)
     
  • Crude Oil

    74.86
    +0.88 (+1.19%)
     
  • Gold

    1,748.80
    -2.90 (-0.17%)
     
  • Silver

    22.37
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1700
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    18.09
    -0.54 (-2.90%)
     
  • GBP/USD

    1.3695
    +0.0014 (+0.10%)
     
  • USD/JPY

    110.9520
    +0.2670 (+0.24%)
     
  • BTC-USD

    43,629.87
    +205.13 (+0.47%)
     
  • CMC Crypto 200

    1,087.62
    -15.44 (-1.40%)
     
  • FTSE 100

    7,075.37
    +23.89 (+0.34%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

If You Had Bought Charles River Laboratories International (NYSE:CRL) Stock Five Years Ago, You Could Pocket A 214% Gain Today

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. For instance, the price of Charles River Laboratories International, Inc. (NYSE:CRL) stock is up an impressive 214% over the last five years. Also pleasing for shareholders was the 19% gain in the last three months. But this could be related to the strong market, which is up 18% in the last three months.

Check out our latest analysis for Charles River Laboratories International

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

During five years of share price growth, Charles River Laboratories International achieved compound earnings per share (EPS) growth of 14% per year. This EPS growth is slower than the share price growth of 26% per year, over the same period. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth.

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

earnings-per-share-growth
earnings-per-share-growth

It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..

A Different Perspective

We're pleased to report that Charles River Laboratories International shareholders have received a total shareholder return of 67% over one year. That gain is better than the annual TSR over five years, which is 26%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. It's always interesting to track share price performance over the longer term. But to understand Charles River Laboratories International better, we need to consider many other factors. Take risks, for example - Charles River Laboratories International has 2 warning signs we think you should be aware of.

Charles River Laboratories International is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.